Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JAR-2203
- Development stage
- Phase 1
- Lead developer
- Oceanpine Capital
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
JAR-2203 is a small interfering RNA (siRNA) therapeutic designed to treat hyperlipoproteinemia(a) by lowering elevated levels of lipoprotein(a) [Lp(a)]. Developed by Jacobio-Raikang, a cardiometabolic incubator company of Jacobio Pharmaceuticals, JAR-2203 utilizes RNA interference (RNAi) to target and degrade the mRNA of the LPA gene in the liver. This action inhibits the synthesis of apolipoprotein(a), a key component of Lp(a). Elevated Lp(a) is a genetically determined, independent risk factor for cardiovascular diseases such as coronary artery disease, stroke, and aortic stenosis. JAR-2203 is administered subcutaneously and is currently in Phase I clinical development.
- Other names
- JAR-2203 InjectionJAR2203 InjectionJAR 2203 InjectionJAR-2203注射液
02
Targets
AGO2 (Argonaute RISC catalytic component 2)LPA (Lysophosphatidic acid)
Beyond the preview
Go deeper on JAR-2203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JAR-2203.